Cargando…

Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review

BACKGROUND AND OBJECTIVE: Non-tuberculous mycobacterial lung disease (NTM-LD) manifests with bronchiectasis, inflammatory bronchiolitis, nodules, and/or cavitation. Bronchiectasis is characterized by permanently dilated airways wherein mucus accumulates, creating a vicious cycle of chronic injurious...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssefnia, Artmis, Pierre, Alicia, Hoder, Jeffrey M., MacDonald, Michelle, Shaffer, Monica J. B., Friedman, Jessica, Mehler, Philip S., Bontempo, Amanda, da Silva, Francisco C. N., Chan, Edward D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562528/
https://www.ncbi.nlm.nih.gov/pubmed/36245600
http://dx.doi.org/10.21037/jtd-22-410
_version_ 1784808194048000000
author Youssefnia, Artmis
Pierre, Alicia
Hoder, Jeffrey M.
MacDonald, Michelle
Shaffer, Monica J. B.
Friedman, Jessica
Mehler, Philip S.
Bontempo, Amanda
da Silva, Francisco C. N.
Chan, Edward D.
author_facet Youssefnia, Artmis
Pierre, Alicia
Hoder, Jeffrey M.
MacDonald, Michelle
Shaffer, Monica J. B.
Friedman, Jessica
Mehler, Philip S.
Bontempo, Amanda
da Silva, Francisco C. N.
Chan, Edward D.
author_sort Youssefnia, Artmis
collection PubMed
description BACKGROUND AND OBJECTIVE: Non-tuberculous mycobacterial lung disease (NTM-LD) manifests with bronchiectasis, inflammatory bronchiolitis, nodules, and/or cavitation. Bronchiectasis is characterized by permanently dilated airways wherein mucus accumulates, creating a vicious cycle of chronic injurious inflammation and recurrent infections. While antibiotics are an important part of the treatment of NTM-LD, airway clearance techniques to mitigate this pathogenic mechanism of bronchiectasis as well as other ancillary measures are also important components of NTM-LD treatment. The objective of this contemporaneous Narrative Review is to emphasize the importance of such ancillary measures. METHODS: We searched PubMed for the key words of “airway clearance”, “pulmonary rehabilitation”, “nutrition”, “swallowing dysfunction”, “gastroesophageal reflux”, “vestibular dysfunction”, or “cochlear dysfunction” with that of “non-tuberculous mycobacterial lung disease”, “bronchiectasis”, or “respiratory disease”. The bibliographies of identified articles were further searched for relevant articles not previously identified. Each relevant article was reviewed by one or more of the authors and a narrative review was composed. KEY CONTENT AND FINDINGS: Herein, we discuss five ancillary treatment measures that are pertinent to patients with bronchiectasis and NTM-LD: (I) airway clearance; (II) physical and pulmonary rehabilitation; (III) nutrition; (IV) diagnosis and mitigation of swallowing dysfunction and of gastroesophageal reflux disease (GERD); and (V) minimization of vestibular and cochlear dysfunction associated with some anti-NTM drugs. CONCLUSIONS: While antibiotics is often the central focus of treatment of NTM-LD, given its propensity for recurrent and recalcitrant infection, other ancillary measures to break the vicious cycle of injurious inflammation and infection should also be emphasized to optimize treatment success.
format Online
Article
Text
id pubmed-9562528
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-95625282022-10-15 Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review Youssefnia, Artmis Pierre, Alicia Hoder, Jeffrey M. MacDonald, Michelle Shaffer, Monica J. B. Friedman, Jessica Mehler, Philip S. Bontempo, Amanda da Silva, Francisco C. N. Chan, Edward D. J Thorac Dis Review Article BACKGROUND AND OBJECTIVE: Non-tuberculous mycobacterial lung disease (NTM-LD) manifests with bronchiectasis, inflammatory bronchiolitis, nodules, and/or cavitation. Bronchiectasis is characterized by permanently dilated airways wherein mucus accumulates, creating a vicious cycle of chronic injurious inflammation and recurrent infections. While antibiotics are an important part of the treatment of NTM-LD, airway clearance techniques to mitigate this pathogenic mechanism of bronchiectasis as well as other ancillary measures are also important components of NTM-LD treatment. The objective of this contemporaneous Narrative Review is to emphasize the importance of such ancillary measures. METHODS: We searched PubMed for the key words of “airway clearance”, “pulmonary rehabilitation”, “nutrition”, “swallowing dysfunction”, “gastroesophageal reflux”, “vestibular dysfunction”, or “cochlear dysfunction” with that of “non-tuberculous mycobacterial lung disease”, “bronchiectasis”, or “respiratory disease”. The bibliographies of identified articles were further searched for relevant articles not previously identified. Each relevant article was reviewed by one or more of the authors and a narrative review was composed. KEY CONTENT AND FINDINGS: Herein, we discuss five ancillary treatment measures that are pertinent to patients with bronchiectasis and NTM-LD: (I) airway clearance; (II) physical and pulmonary rehabilitation; (III) nutrition; (IV) diagnosis and mitigation of swallowing dysfunction and of gastroesophageal reflux disease (GERD); and (V) minimization of vestibular and cochlear dysfunction associated with some anti-NTM drugs. CONCLUSIONS: While antibiotics is often the central focus of treatment of NTM-LD, given its propensity for recurrent and recalcitrant infection, other ancillary measures to break the vicious cycle of injurious inflammation and infection should also be emphasized to optimize treatment success. AME Publishing Company 2022-09 /pmc/articles/PMC9562528/ /pubmed/36245600 http://dx.doi.org/10.21037/jtd-22-410 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Youssefnia, Artmis
Pierre, Alicia
Hoder, Jeffrey M.
MacDonald, Michelle
Shaffer, Monica J. B.
Friedman, Jessica
Mehler, Philip S.
Bontempo, Amanda
da Silva, Francisco C. N.
Chan, Edward D.
Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review
title Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review
title_full Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review
title_fullStr Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review
title_full_unstemmed Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review
title_short Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review
title_sort ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562528/
https://www.ncbi.nlm.nih.gov/pubmed/36245600
http://dx.doi.org/10.21037/jtd-22-410
work_keys_str_mv AT youssefniaartmis ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview
AT pierrealicia ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview
AT hoderjeffreym ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview
AT macdonaldmichelle ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview
AT shaffermonicajb ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview
AT friedmanjessica ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview
AT mehlerphilips ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview
AT bontempoamanda ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview
AT dasilvafranciscocn ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview
AT chanedwardd ancillarytreatmentofpatientswithlungdiseaseduetonontuberculousmycobacteriaanarrativereview